Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Toilet rats? Washington health officials warn of possible rodents in sewer systems after floods - 2Russia downs 16 drones heading for Moscow, mayor says
- 3UK to hold fresh pork, other affected Spanish products at border amid African swine fever outbreak
- 4'The best gift ever': Baby is born after the rarest of pregnancies, defying all odds
- 5Architect Frank Gehry has died: See his most iconic buildings
- Illustrations Gained from a Crosscountry Excursion
- The most effective method to Offset Album Rates with Liquidity Needs
- College students are now slightly less likely to experience severe depression, research shows – but the mental health crisis is far from over
- Netflix's Eddie Murphy documentary explains 'Saturday Night Live' beef: 'That's why I didn't go back for years'
- 8 Fundamental Stages: Novice's Manual for Secure Your Android with a VPN
- A new mom skipped a routine appointment. An infected cut led to a devastating diagnosis
- Step by step instructions to Guarantee the Strength and Life span of Your Pre-assembled Home
- Interstellar comet 3I/ATLAS to pass closest to Earth on Friday
- Was This Driver Simply Having Some good times Or Behaving Like An Ass?
